BIOCON BIOLOGICS INC announced the FDA approval of its generic version of WARRIOR PHARMA INC.'s Granix (filgrastim-sndz) on Wednesday, likely sparking immediate competition in the neutropenia market and pressuring WARRIOR PHARMA's product margins. This clearance significantly expands BIOCON’s footprint in the oncology biosimilars space, providing a new revenue stream while increasing supply volume for a high-demand treatment in the hematology sector.